FDA Blood Safety Regulations: Enforcement, Inspections, and Standards

The Food and Drug Administration (FDA) is the primary regulatory authority overseeing the safety of the U.S. blood supply. Its framework for blood bank oversight — developed over decades through trial, public pressure, and legislative action — covers everything from donor eligibility to post-transfusion incident reporting. Understanding this system helps patients, donors, and healthcare workers know what protections are in place and where their limits lie.

What Is the FDA’s Role in Blood Safety?

The FDA’s Center for Biologics Evaluation and Research (CBER) sets and enforces standards for blood collection, processing, testing, storage, and distribution. Facilities that collect, process, or distribute blood are required to register with the FDA and comply with regulations set out in Title 21 of the Code of Federal Regulations.

The FDA began formally regulating blood resources in 1972, established inspection standards by 1977, and has progressively strengthened requirements in response to safety failures — most notably the HIV and hepatitis C crises of the 1980s and 1990s.

What Are the Five Layers of the FDA’s Blood Safety System?

1. Donor Screening

Before blood is collected, donors complete a health and lifestyle questionnaire designed to identify risk factors for blood-borne infections. Temporary or permanent deferrals are triggered by factors including recent travel to malaria-endemic areas, certain medications, recent tattoos or piercings, or a history of intravenous drug use.

A well-documented limitation: the United States relies on the honor system — donors must tell the truth. There is no way to verify every answer. FDA enforcement reports have documented cases where donors with known disqualifying factors were collected from anyway.

2. Blood Testing

Every donated unit is tested for a mandated panel of pathogens after collection. Required tests include:

• ABO blood typing and Rh factor determination
• HIV-1 and HIV-2 antibodies
• Hepatitis B surface antigen (HBsAg) using third-generation assays (RIA, RPHA, or ELISA/EIA)
• Hepatitis B core antibody (anti-HBc)
• Hepatitis C virus antibody (anti-HCV)
• HTLV-1 and HTLV-2 antibodies
• Syphilis (serologic test)
• Alanine aminotransferase (ALT) as an indirect marker of liver health
• Nucleic acid amplification testing (NAT) for HIV and HCV (standard since the early 2000s)

Repeatedly reactive results require confirmation with follow-up Western blot or other confirmatory testing. All positive donors are added to deferred donor registries to prevent future donations.

3. Deferral Lists

Blood banks must maintain databases of deferred donors and screen new donors against them. A documented weakness in the system is that this registry is not nationally coordinated — a donor deferred at one facility could theoretically donate at another if records aren’t shared. The FDA has pushed for improved interoperability.

4. Quarantine

Blood units are quarantined until all required testing is completed. Units that test reactive for any pathogen are destroyed and never released for transfusion. Units from donors in the window period — where infection exists but tests haven’t yet turned positive — represent the residual risk in an otherwise well-tested supply.

5. Investigation and Reporting

Licensed blood establishments are required to report manufacturing deviations, accidents, and fatalities to CBER. Fatal transfusion complications require immediate reporting. Unlicensed facilities are strongly encouraged to report voluntarily. These reports feed into FDA enforcement actions and supply-wide safety improvements.

What Do FDA Inspections Cover?

FDA inspections of blood banks are comprehensive, assessing multiple areas of operations:

Facility and Personnel Requirements

• Hand-washing facilities must be accessible for all staff handling blood
• Donor interview areas must provide adequate privacy
• Unauthorized personnel are barred from collection areas
• All staff must be trained on the regulations relevant to their roles — including volunteers and mobile site workers
• Training documentation must be maintained and available for inspection

Equipment Standards

• All equipment must be calibrated and maintained according to manufacturer specifications
• Refrigeration temperature logs must be maintained continuously
• Equipment failure must be documented and corrected before affected units are released

Records and Documentation

• Blood banks must track all unsuitable donors to prevent distribution of their units
• Deferral records and repeatedly reactive test results must be documented and accessible
• Licensed establishments must report manufacturing changes to CBER
• Computer systems controlling critical manufacturing steps must have validation documentation and audit trails

Testing Quality Controls

• ABO and Rh typing reagents must include both positive and negative controls
• Anti-Human Globulin reagent requires daily testing with sensitized cells
• Proficiency testing programs are mandatory for HBsAg and anti-HIV testing
• Platelets require monthly quality control checks including platelet counts, pH determination, and plasma volume measurement at the end of storage

Blood Component Storage Standards

The FDA sets specific storage and dating requirements for all blood components:

Donor Suitability Standards

Temperature requirements are precise: a reading of 99.6°F (37.5°C) or higher on donation day results in temporary deferral. Deferral periods for specific exposures include:

• 12-month deferral for viral hepatitis exposure
• 12-month deferral for needlestick or bloodborne pathogen exposure
• 12-month deferral for receiving blood or blood components
• 72-hour deferral following tooth extraction

How Does the FDA Handle Enforcement Actions?

When inspections find violations, the FDA has several enforcement tools:

Warning Letters identify specific violations and require corrective action. They become public record and are published on the FDA website.

Consent Decrees are legally binding agreements between the FDA and a facility, requiring specific improvements under court oversight. They have been used against major blood centers and plasma manufacturers.

License Revocation is reserved for the most serious and persistent violations — effectively shutting down a facility’s ability to collect or distribute blood.

Recalls and Withdrawals are required when distributed blood products are found to be potentially unsafe. The FDA publishes weekly enforcement reports documenting each recall. These reports cover blood and blood products that were already tested, processed, and in some cases distributed to patients before the issue was identified.

What Are the Known Weaknesses in FDA Oversight?

Documented concerns, many surfacing in Congressional investigations and FDA enforcement records, include:

The honor system: Donor self-screening depends entirely on truthful answers. Donors who know they’re ineligible but donate anyway can compromise safety in ways testing alone can’t catch.

Advance inspection notice: A 1996 Congressional report found that the FDA was giving some plasma fractionation companies advance notice of inspections — inconsistent with how other regulated industries are treated and potentially allowing companies to temporarily correct problems before inspectors arrived.

Window period gaps: No testing system can detect infections in the window period between exposure and detectability. NAT testing has shortened this significantly, but a residual gap remains.

Bacterial contamination: Platelet units stored at room temperature are particularly susceptible to bacterial growth. No routine, cost-effective bacterial screening was in place for many years — a gap that the FDA has worked to address with newer pathogen reduction technologies.

For the broader history of blood supply safety failures, Congressional investigations, and systemic reforms, see is the blood supply safe.